Status:
COMPLETED
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Lead Sponsor:
BeiGene
Conditions:
Esophageal Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity ...
Eligibility Criteria
Inclusion
- Key
- Histologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC).
- Have progressive disease during or after first-line of systemic treatment for unresectable, locally advanced, recurrent or metastatic ESCC.
- Have measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Have confirmed programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% in tumor tissues tested by the central lab.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- Key
Exclusion
- Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
- Participants with evidence of fistula (either esophageal/bronchial or esophageal/aorta).
- Evidence of complete esophageal obstruction not amenable to treatment.
- Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within 2 weeks after intervention).
- Has received any chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin, etc) or any investigational therapies within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug. Or has received palliative radiation treatment or other local regional therapies within 14 days before the first dose of study drug.
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
March 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 26 2023
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT04732494
Start Date
March 31 2021
End Date
December 26 2023
Last Update
January 31 2025
Active Locations (86)
Enter a location and click search to find clinical trials sorted by distance.
1
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230088
2
Quanzhou First Hospital of Fujian Province
Quanzhou, Fujian, China, 362002
3
First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361003
4
Lanzhou University Second Hospital
Gansu, Gansu, China